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Abstract The aim of this study was to investigate the
expressions of Toll-like receptor (TLR) 2, TLR4, TLR9,
and their correlations with the expression of cytokines that
are associated with activation of CD4
+ T cells and
inflammation including interferon γ (IFNγ), interleukin 4
(IL4), interleukin 17 (IL17), and tumor necrosis factor α
(TNFα) in muscle tissues of patients with dermatomyositis
(DM) and polymyositis (PM). The expressions of TLR2,
TLR4, TLR9, IFNγ, IL4, IL17, and TNFα were measured
by real-time reverse transcription–polymerase chain reac-
tion in muscle tissues from 14 patients with DM and PM
(nine patients with DM, five patients with PM) and three
controls. The expressions of TLR2, TLR4, and TLR9 were
also localized with immunohistochemistry. The expression
levels of TLR2, TLR4, TLR9, IFNγ, IL4, IL17, and TNFα
were significantly high in patients with DM and PM
compared with those in the controls, and the expression
levels of TLR4 and TLR9 had significant positive correla-
tions with the expressions of IFNγ, IL4, IL17, and TNFα.
Immunohistochemistry showed that TLR2, TLR4, and
TLR9 were expressed by infiltrating cells of perimysium
in DM, whereas they were expressed by infiltrating cells of
endomysium in PM. These results suggest that the
involvement of TLR4 and TLR9 in immunopathogenesis
of DM and PM might be connected with activation of
CD4
+ T cells.
Keywords Dermatomyositis.Polymyositis.Toll-like
receptors
Introduction
Dermatomyositis (DM) and polymyositis (PM) are chronic
muscle disorders characterized by inflammatory infiltrate in
the muscle tissue. DM and PM are clinically characterized
by features of symmetric proximal muscle weakness
associated with muscle cell destruction [1]. Previous studies
have identified different proportions of CD4
+, CD8
+ T cells
and macrophages with various localizations in DM and PM.
In PM, cytotoxic CD8
+ T cells and macrophages were
detected surrounding and invading non-necrotic muscle
fibers expressing major histocompatibility complex (MHC)
class I [2]. In DM, perivascular infiltrates composed mainly
of CD4
+ T cells, B cells, and macrophages were observed
[3].
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of effector and regulatory T cells (Tregs) from naive
CD4
+ T cell precursors is a hallmark of the adaptive
immune system. T helper (Th) 1 and Th2 are the best
understood effector CD4
+ T cells generated during
immune responses, with each subset characterized by
distinct transcription factor activity and cytokine-secreting
phenotype. Classically, Th1 cells produce interferon (IFN)
γ and mediate immune responses against intracellular
bacteria, viruses, and tumor cells through the activation of
macrophages and cytotoxic T cells. Th2 cells make mostly
interleukin 4 (IL4), which stimulate humoral responses
and are thought to have evolved to enhance resistance
against extracellular parasites [4, 5]. In recent years, a
distinct T-cell subset, termed Th17 cells, has also been
identified and seems to play key roles in the activation of
neutrophils and immunity to bacteria, particularly at
mucosal surfaces. IL17, also termed IL17A, is the
signature cytokine of Th17 cells [6].
Recently reported data suggest that CD4
+ T cells play
roles in immunopathogenesis of DM and PM [7].
Identification of Th1 and Th17 cytokine (IFNγ and
IL17) producing cells from muscle tissue of DM and PM
contributes to the roles of CD4
+ Tcells in DM and PM [8].
Cytokines are potent mediators of a number of cell
functions and are essential in coordinating inflammatory
responses. They can be produced by a large variety of cells
and exhibit pro-inflammatory as well as anti-inflammatory
effects. Their key role in chronic inflammatory diseases has
been well documented by the often strikingly good
response to therapies targeting proinflammatory cytokines,
one of the best examples being tumor necrosis factor (TNF)
α blockade in patients with rheumatoid arthritis and
Crohn’s disease. Recent findings suggest cytokines as
important key molecules in the pathogenic mechanisms of
idiopathic inflammatory myopathies (IIMs), myositis [9].
Toll-like receptors (TLRs) are primarily involved in the
innate immune response to microbial pathogens through the
recognition of conserved pathogen-associated molecular
patterns. However, they also contribute to sterile inflam-
mation by sensing “danger signals”, the endogenous
molecules that are generated during tissue damage or
inflammation [10–13]. The activation of TLRs is an
important bridge between innate and adaptive immunity
by regulating the expression of co-stimulatory molecules on
antigen-presenting cells that drive T-cell activation and by
creating a cytokine milieu in which the differentiation of T
cells into the desired subsets occurs [14]. It was known that
activation of TLR4 and TLR9 is generally to induce a Th1
response in dendritic cells (DCs), and TLR2 might induce
Th2-based immune response in experimental asthma, and
activation of TLR4 also induces Th17 response through
IL17 production [14–21].
The aim of this study was to investigate the expression
of TLR2, TLR4, TLR9, and cytokines that are related to
activation of CD4
+ T cells (Th1, Th2, and Th17 cells) and
inflammations including IFNγ, IL4, IL17, and TNFα, and
to examine the connection of TLRs to these cytokines in
muscle tissues of patients with DM and PM.
Here, we demonstrate that the TLR4 and TLR9
expressions are significantly increased, and they are
connected with the expressions of those cytokines in
muscle tissues of patients with DM and PM.
Patients and methods
Patients
Muscle biopsy samples from patients newly diagnosed with
active DM (n= 9 )o rP M( n=5), according to the classifi-
cation system of Bohan and Peter [22, 23], were evaluated
in this study. Seven patients were women and seven were
men. The time from symptom onset to diagnosis was 1–
12 months, and they had not been treated. The mean age at
diagnosis was 41 years (41±14 years). Patient data are
presented in Table 1. Muscle tissue sections from three
patients with non-specific muscle manifestations but normal
histological findings were used as the controls. All patients
and controls gave their informed consent, and the local
ethics committee at Pusan National University Hospital
approved the study.
Laboratory assessments
Serum levels of C-reactive protein (CRP), the erythrocyte
sedimentation rate (ESR), and serum aldolase and creatinine
kinase (CK) levels were analyzed at the Department of
Clinical Chemistry, Pusan National University Hospital.
Muscle biopsies
Biopsy samples were obtained from the vastus lateralis or
deltoid muscle with a “semi-open” muscle biopsy technique,
with the patient under local anesthesia. The biopsy specimens
were immediately frozen in dry ice and isopentane and stored
at −70°C until analysis.
Real-time RT–PCR
After biopsy of the muscle tissues from patients with PM or
DM, these were immersed immediately in liquid nitrogen.
Total RNA was extracted from the frozen muscle biopsies
withTRIzolReagent(InvitrogenLifeTechnologies,Carlsbad,
CA, USA). Each solution containing 1 μg of RNA was
heated at 65°C for 15 min, and a mixture containing
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was transcribed with reaction cycles of 25°C for 10 min,
42°C for 60 min, 99°C for 5 min, and 4°C for 5 min. A
First Strand cDNA Synthesis Kit for reverse transcription–
polymerase chain reaction (RT–PCR; AMV, Roche Applied
Science, Indianapolis, IN, USA) was used for the reactions
described above, and real-time PCR was performed in a
LightCycler System Instrument (Roche Applied Science).
LightCycler-DNA Master SYBR Green I (Roche Applied
Science), the cDNA template, each primer, and 25 mM of
MgCl2 were added to microcapillary tubes to a final volume
of 20 μl. The PCR cycling parameters were 50 cycles of
denaturation at 95°C for 10 s, annealing at 60°C for 5 s, and
primer extension at 72°C for 20 s.
The primers 5′-GCCACCATTTCCACGGACT-3′ (sense)
and 5′-GGCTTCCTCTTGGCCTGG-3′ (antisense) were used
to amplify TLR2,5′-CTCTGCCTTCACTACA GAGACTTT-
3′ (sense) and 5′-TGTGGAAGC CTTCCTGGATG-3′
(antisense) for TLR4, 5′-ACTGAGCACCCCTGCTTCTA-3′
(sense) and 5′-AGATTAGTCACGG CAGGAA-3′ (antisense)
for TLR9, 5′-TCCCATGGGTTGTGTGTTTA-3′ (sense) and
5′-AAGCA CCAGGCATGAAATCT-3′ (antisense) for IFNγ,
5′-ACCCAAACTAGGCCTCACCT-3′ (sense) and 5′-
ACAGGTGGCATCTTGGAAAC-3′ (antisense) for IL4,
5′-TCTCAT CCAGCAAGAGATCC-3′ (sense) and 5′-
AGTTTGGGACCCCTTTACAC-3′ (antisense) for IL17, and
5′-CAAACCACCAAGTGGAGGAG-3′ (sense) and 5′-
AGATAGCAAATC GGCTGACG-3′ (antisense) for TNFα,
all purchased from Bioneer (Daejun, Korea).
The threshold cycle (CT) was determined by monitoring
the fluorescent signal for each cycle, and the amounts of
mRNA in the experimental groups were determined relative
to those of the control group.
Immunohistochemistry for TLR2, TLR4, and TLR9
The cryotissue was fixed in 4% paraformaldehyde, and
endogenous peroxidase activity was quenched with 3%
H2O2 in methanol. Immunohistochemistry was performed
using the Vectastain ABC kit (Vector Laboratories, Burlin-
game, CA, USA). The tissues were incubated with the
primary antibody directed against TLR2 (sc-8689), TLR4
(sc-10741), or TLR9 (sc16247) overnight at 4°C. All the
primary antibodies were purchased from Santa Cruz
Biotechnology, Inc. The slides were incubated with biotiny-
lated secondary antibody solution and then treated with the
avidin/biotinylated enzyme complex. The final color product
was developed using diaminobenzidine chromogen (Dako,
Carpinteria, CA, USA).
Statistical analysis
Differences between experimental groups were tested using
the Mann–Whitney U test and Student’s t test, depending
Table 1 Clinical and laboratory characteristics and the expression of TLR2, TLR4, TLR9, IFNγ, IL4, IL17, and TNFα in 14 patients with DM
and PM
Patient/
diagnosis
Sex Age Symptom
duration,
months
CK
(U/l)
Aldolase
(U/l)
ESR
(mm/h)
CRP
(mg/dl)
Relative mRNA expression levels compared to controls
a
TLR2 TLR4 TLR9 IFNγ IL4 IL17 TNFα
1/DM F 66 1 502 10.1 85 3.41 16.4 48.4 11.2 587 9.4 40 9.5
2/DM M 36 3 2,815 46.1 75 0.9 18.6 140 15.1 1,430 23.3 68 27
3/DM M 39 2 1,163 7.1 85 0.5 25.1 164 5.6 278 4.6 18 3.7
4/DM M 37 12 70 5.7 78 0.5 15.1 106 11.6 484 6.7 27 13.9
5/DM M 58 1 3,006 8.4 13 0.5 48.1 60.8 4.6 273 1.8 9 4.8
6/DM M 37 2 14,139 36.7 73 2.8 57.1 81 6.0 462 5.3 19 21.7
7/DM M 55 1 3,034 21.9 24 2.3 13.1 153 37.2 885 15.3 62 17.1
8/DM F 30 6 6,000 54.3 14 0.1 69.8 232 26.3 2,760 23.7 100 20.2
9/DM F 18 3 668 16.5 52 0.1 28.7 297 34.4 3,140 71.0 122 82.5
10/PM F 47 2 10,994 109.5 37 0.4 18.6 169 14.8 674 15.9 75 31.3
11/PM M 22 3 32 6.9 26 1.3 16.1 149 10.0 382 4.7 22 8.2
12/PM F 59 1 2,207 44 108 1.8 50.3 228 35.2 1,830 22.6 139 23.5
13/PM F 33 7 2,743 64 50 1.0 39.5 444 44.0 2,180 47.1 218 50.5
14/PM F 48 1 1,820 44.8 19 0.6 35.9 108 5.2 334 3.4 11 3.2
DM/PM
(9/5)
M/F
(7/7)
41±
14
3.2±3.1 3,510±
4,180
34±30 53±
31
1.2±
1.0
32.3±
18.1
170.0±
104.8
18.6±
13.8
1,121.3±
978.9
18.1±
19.5
66.4±
60.6
22.7±
21.5
aThe mRNA expressions were showed by relative levels compared to controls. Muscle tissue sections from three patients with non-specific
muscle manifestations but normal histological findings were used as the controls
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standard deviations (SD).
Results
The expression levels of TLR2, TLR4, TLR9, IFNγ,I L 4 ,
IL17, and TNFα were significantly high in patients with DM
and PM compared to controls
The mRNA expression levels of TLR2 (32.3±18.1), TLR4
(170.0±104.8), TLR9 (18.6±13.8), IFNγ (1121.3±978.9),
IL4 (18.1±19.5), IL17 (66.4±60.6), and TNFα (22.7±
21.5) were significantly high in patients compared to those
of the controls, and the levels of TLR4 and IFNγ were
prominently high (Table 1). These expression levels were
not significantly different between PM and DM, and any of
these levels did not significantly correlate with disease
duration, age, serum level of ESR, CRP, CK, and aldolase.
The expression levels of TLR4 and TLR9 had significant
positive correlations with those of IFNγ, IL4, IL17,
and TNFα
The expression levels of TLR2 had no significant
correlations with those of IFNγ,I L 4 ,I L 1 7 ,a n dT N F α,
whereas the levels of TLR4 and TLR9 had positive
correlations with those of IFNγ (r= 0 . 7 6i nT L R 4a n d
0.73 in TLR9, p<0.01), IL4 (r=0.8 in TLR4 and 0.76 in
TLR9, p<0.01), IL17 (r= 0 . 9 2i nT L R 4a n d0 . 9i nT L R 9 ,
p<0.01), and TNFα (r= 0 . 7 1i nT L R 4 ,p<0.01; 0.66 in
TLR9, p=0.01; Fig. 1).
Immunohistochemistry of TLR2, TLR4, and TLR9
TLR2, TLR4, and TLR9 were expressed by perimysial
infiltrating cells in DM, whereas they were expressed by
endomysial infiltrating cells in PM (Figs. 2, 3, and 4).
Discussion
Data originating predominantly from animal models of
autoimmune disease and circumstantial data from human
patients suggest that the inappropriate activation of the TLR
pathway by endogenous or exogenous ligands may lead to
the initiation and/or perpetuation of autoimmune responses
and tissue injury [24]. The expression of TLRs by both
immune cells and the resident cells in the involved tissues
supports their important roles in tissue injury, destruction,
and repair. We showed that the expression levels of TLR2,
TLR4, and TLR9 were elevated in the muscle tissues of
patients with DM and PM compared to controls, and as far
as we know, this is the first report of this phenomenon in
DM and PM.
We reported that inflammatory cytokines such as IL17,
TNFα, IL1, and IL6 increase the production of TLR2,
TLR4, and TLR9 from mice synoviocytes in autoimmune
arthritis [25]. The possible mechanisms of TLR over-
expressions are as follows: (1) various microbial pathogens
considered as etiologic agents of IIMs contribute to over-
expressions; (2) endogenous molecules and cytokines that
are generated during muscle damage or immune response
induce the overexpressions.
DM is a microangiopathy affecting the skin and muscle,
in which the early activation and deposition of complement
causes the lysis of endomysial capillaries and muscle
ischemia. In PM, clonally expanded CD8
+ cytotoxic T
cells invade muscle fibers that express MHC class I
antigens, leading to fiber necrosis via the perforin pathway.
Perimysial and perivascular inflammation with CD4
+ Tcell,
B cells, and macrophage infiltrations are histological
features of DM, whereas endomysial inflammation with
CD8
+ T-cell infiltration is a histological feature of PM [1].
We have demonstrated that TLR2, TLR4, and TLR9 are
expressed by perimysial infiltrating cells in DM and by
endomysial infiltrating cells in PM. These expression
patterns of TLR2, TLR4, and TLR9 were consistent with
the histopathological features of DM and PM.
CD4
+ T cells play roles in immunopathogenesis of DM
and PM [7]. Detection of IFNγ and IL17 producing cells in
muscle tissues of DM and PM suggests the involvement of
activated CD4
+ T cells in the pathophysiology of both DM
and PM. These data showed that non-specific amplification
of muscle inflammation by T lymphocytes may result from
the local production of cytokines and chemokines [8]. We
have demonstrated that the expressions of cytokines that are
associated with CD4
+ T-cell activation including IFNγ
(Th1 cytokine), IL4 (Th2 cytokine), and IL17 (Th17
cytokine) were increased in patients with DM and PM
compared to controls. These results imply that activation of
CD4
+ T cells is involved in immunopathogenesis of DM
and PM.
TLR signaling may promote autoimmunity by several
mechanisms. TLR signaling of B lymphocytes enhance
their antigen-presenting capacity towards CD4
+ T cells
through up-regulation of HLA-DR. TLR signaling in
plasmacytoid DCs results in maturation of DCs, and mature
DCs promote induced activation of CD4
+ T cells [24].
CD4
+ T cells are categorized as Th1, Th2, or Th17 cells,
and the function of these cells is to produce reciprocal sets
of cytokines: IFNγ by Th1 cells, IL4 by Th2 cells, and
IL17 by Th17 cells [4–6]. Specific TLRs might be
associated with CD4
+ T-cell activation. Activation of
TLR2 might induce Th2 immune response, TLR4 induced
Th1 and Th17 immune response, and TLR9 induced Th1
276 Clin Rheumatol (2010) 29:273–279immune response [14–21]. We showed that the expression
levels of TLR4 and TLR9 were increased compared to
controls and had significant positive correlations with those
of IFNγ, IL4, and IL17. These results suggest that the
overexpression of TLR4 and TLR9 might be involved in
the immunopathogenesis of DM and PM through activation
of Th1, Th2, and Th17 cells. And the data showed by our
study that the expression levels of TLR4 and IFNγ were
Fig. 2 Immunohistochemistry of
TLR2 in muscle tissues of
patients with DM, PM, and
controls. In the muscle tissues of
DM, TLR2 was expressed by
infiltrating cells in the perimysial
area (A3), whereas in PM, TLR2
was expressed by infiltrating
cells in the endomysium (A4).
Control muscle tissues were
obtained from patients with non-
specific muscle manifestations
but with normal histological
findings (A1, 2). Magnification
was ×400
Fig. 1 Correlations of TLR2, TLR4, TLR9, IFNγ, IL4, L17, and
TNFα expressions in patients with DM and PM. The expression
levels of TLR4 and TLR9 had significant positive correlations with
those of IFNγ, IL4, IL17, and TNFα. The mRNA expressions were
measured by real-time RT–PCR from muscle tissues of patients with
DM and PM
Clin Rheumatol (2010) 29:273–279 277prominently high and had significantly positive correlations
with each other suggest that TLR4-induced Th1 response
might play a more important role in immunopathogenesis
of DM and PM.
TNFα gene expression can be detected in the muscle
tissues of most patients with IIMs [26–28]. TNFα acts via
several possible mechanisms, including the positive feed-
back loop in which increased numbers of TNFα-producing
cells in infiltrating cell clusters enhance the inflammatory
r e a c t i o nb yr e l e a s i n gm o r eT N F α. This mediates the
upregulation of adhesion molecules on endothelial cells
and hence increases transendothelial cell trafficking as well
as enhancing the T-cell response and thereby also T-cell-
mediated muscle injury [29, 30]. We have showed that the
expression level of TNFα was elevated and had significant
positive correlations with those of TLR4 and TLR9 in the
muscle tissues of patients with DM and PM.
According to recent studies, including our previous
reported study and our present data, the possible immuno-
pathogenic involvement of TLRs and CD4
+ T cells are as
follows: (1) overexpression of TLR4 and TLR9 induced by
microbial pathogen, endogenous molecules, and inflamma-
tory cytokines contributed to activation of CD4
+ T cells
resulting in increased expression of IFNγ, IL4, and IL17;
(2) overexpressed CD4
+ T-cell cytokines induce the
inflammatory response, resulting in an increase of various
inflammatory cytokines and endogenous molecules; (3)
overexpressed CD4
+ T-cell and inflammatory cytokines,
Fig. 3 Immunohistochemistry of
TLR4 in muscle tissues of
patients with DM, PM, and
controls. In the muscle tissues of
DM, TLR4 was expressed by
infiltrating cells in the perimysial
area (B3), whereas in PM, TLR4
was expressed by infiltrating
cells in the endomysium (B4).
Control muscle tissues were
obtained from patients with non-
specific muscle manifestations
but with normal histological
findings (B1, 2). Magnification
was ×400
Fig. 4 Immunohistochemistry
of TLR9 in muscle tissues of
patients with DM, PM, and
controls. In the muscle tissues of
DM, TLR9 was weakly
expressed by infiltrating cells in
the perimysial area (C3),
whereas in PM, TLR9 was
expressed by infiltrating cells in
the endomysium (C4). Control
muscle tissues were obtained
from patients with non-specific
muscle manifestations but with
normal histological findings
(C1, 2). Magnification was ×400
278 Clin Rheumatol (2010) 29:273–279including IFNγ, IL4, IL17, and TNFα, and endogenous
molecules induce the overexpression of TLRs, causing the
vicious cycle of amplification of chronic inflammation in
muscle tissues of DM and PM.
In conclusion, we have demonstrated that the expressions
of TLR2, TLR4, and TLR9 were elevated in muscle tissue of
patients with DM and PM, and their expression patterns were
consistent with pathophysiology of DM and PM. We also
showed that the expression levels of TLR4 and TLR9 had
significant positive correlations with those of Th1, Th2, and
Th17 cell cytokines. These results suggest that the involve-
ment of TLR4 and 9 in the immunopathogenesis of DM and
PM may be connected with activation of CD4
+ Tc e l l s .
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